How the Inhaled COVID-19 Vaccine Can Help Large-scale Vaccination Program

BEIJING, Dec. 21, 2022 - China is currently pushing COVID-19 vaccination and CanSino's intramuscular and inhaled Covid vaccines have recently been recommended as 2nd boosters in China. The focus will be on the immunocompromised and those aged 60 or above, with priority given to a heterologous regimen.

CanSinoBIO's COVID-19 vaccine for Inhalation, Convidecia Air™, utilizing Aerogen's proprietary aerosol drug delivery technology, shows advantages in the large-scale vaccination program. It is a needle-free, painless and non-invasive option that is administered via a nebulizer, which atomizes the liquid vaccine into tiny particles to be inhaled through the mouth and enter the human respiratory tract and lungs to induce a mucosal immune response as well as humoral and cellular immunity. With that said, it can provide quick, regular and mass-scale protection with easy administration.

Both Convidecia™ and Convidecia Air™ can be safely stored and transported in refrigerator facilities between 2°C to 8°C, which is more favorable in countries with insufficient storage facilities and medical resources. Only one-fifth of the intramuscular injection dosage is required for the inhaled version, making Convidecia Air™ a more effective and efficient alternative for the booster vaccination program, as it can also induce mucosal immunity to achieve triple protection. Convidecia Air™ contains the same ingredients as the intramuscular version of Convidecia™. It is the world's first inhaled COVID-19 vaccine. There is also an additional benefit for the elderly to get inhaled vaccines. People don't need to take off clothes during the cold winter, a critical time for China and the world to curb COVID-19.

Boosting with Convidecia™ or Convidecia Air™ can lead to stronger protection. Several clinical studies support the safety and efficacy profile of CanSinoBIO's intramuscular and inhaled COVID-19 vaccines.

The Phase III data published in The Lancet[1] in December 2021 showed that a single dose of Convidecia™ is efficacious and safe, with an efficacy of 96.0% in preventing severe COVID-19 disease and an overall efficacy of 63.7% 14 days post-vaccination for healthy adults aged 18 and above, without any reported vaccine-related serious adverse events. Booster vaccination with the intramuscular injection of CanSinoBIO's COVID-19 vaccine, Convidecia™, is safe and effective for people aged over 60 years. According to a recent preprint research, a heterologous booster with one dose of Convidecia™ can generate neutralizing antibodies against the Omicron variant 7.5 times higher than those induced by a homologous inactivated vaccine booster[2].

Compared to the intramuscular version, Convidecia Air™ induces stronger antibody levels. Convidecia Air™ provides an added layer of mucosal immunity, in addition to the humoral and cellular immunity induced by regular, traditional types of vaccines. Antibody levels against the Omicron strain are 14 times that of a homologous inactivated vaccine booster and 6 times that of a heterologous recombinant vaccine booster[3]. 12 months post vaccination, the neutralizing antibody levels remain significantly higher than that induced by a homologous inactivated vaccine booster[4].

CanSino's inhaled vaccine is the company's latest technological innovation and at the forefront of global R&D around mucosal immunity. Mucosal immunity is helpful to form a first-line immune barrier to prevent the invasion of the virus into the respiratory tract and prevent severe infections.

1. Source: https://doi.org/10.1016/S0140-6736(21)02753-7
2. Source: https://doi.org/10.1101/2022.06.03.22275983
3. Source: https://doi.org/10.1101/2022.03.08.22271816
4. Source: https://doi.org/10.1080/22221751.2022.2155251

CanSino Biologistics, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin, PRC

info@cansinotech.com

About CanSinoBIO

CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) is a leading biopharmaceutical company committed to the research, production, and commercialization of innovative vaccines for global public health security. It possesses five integrated platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant VLP technology, mRNA vaccine technology, and formulation and delivery technology. It has a rich portfolio of pipeline products that help to prevent 12 diseases, including Asia's most innovative vaccine for the Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia™, which is recognized by the WHO, and the ground-breaking inhaled COVID-19 vaccine Convidecia Air™. Additional information can be found online at www.cansinotech.com.

This release was published on openPR.